LASMIDITAN SUCCINATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for lasmiditan succinate and what is the scope of freedom to operate?
Lasmiditan succinate
is the generic ingredient in one branded drug marketed by Eli Lilly And Co and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.Lasmiditan succinate has eighty-five patent family members in forty-three countries.
One supplier is listed for this compound.
Summary for LASMIDITAN SUCCINATE
| International Patents: | 85 |
| US Patents: | 2 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 17 |
| Patent Applications: | 1 |
| DailyMed Link: | LASMIDITAN SUCCINATE at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for LASMIDITAN SUCCINATE
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for LASMIDITAN SUCCINATE
Paragraph IV (Patent) Challenges for LASMIDITAN SUCCINATE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| REYVOW | Tablets | lasmiditan succinate | 50 mg and 100 mg | 211280 | 1 | 2024-01-31 |
US Patents and Regulatory Information for LASMIDITAN SUCCINATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-003 | Dec 18, 2020 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-003 | Dec 18, 2020 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-001 | Jan 31, 2020 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-002 | Jan 31, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-003 | Dec 18, 2020 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-001 | Jan 31, 2020 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-001 | Jan 31, 2020 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LASMIDITAN SUCCINATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-002 | Jan 31, 2020 | ⤷ Sign Up | ⤷ Sign Up |
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-001 | Jan 31, 2020 | ⤷ Sign Up | ⤷ Sign Up |
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-003 | Dec 18, 2020 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for LASMIDITAN SUCCINATE
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Dominican Republic | P2019000139 | COMPOSICIONES Y MÉTODOS RELACIONADOS CON AGONISTAS DE PIRIDINOILPIPERIDINA 5-HT1F | ⤷ Sign Up |
| Ecuador | SP19040190 | COMPOSICIONES Y MÉTODOS RELACIONADOS CON AGONISTAS DE PIRIDINOILPIPERIDINA 5-HT1F | ⤷ Sign Up |
| Morocco | 52920 | COMPOSITIONS ET PROCÉDÉS SE RAPPORTANT À DES AGONISTES DE PYRIDINOYLPIPÉRIDINE 5-HT1F | ⤷ Sign Up |
| Mexico | 2021014139 | COMPOSICIONES Y MÉTODOS RELACIONADOS CON AGONISTAS DE PIRIDINOILPIPERIDINA 5-HT1F. (COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS.) | ⤷ Sign Up |
| Peru | 20191134 | COMPOSICIONES Y METODOS RELACIONADOS CON AGONISTAS DE PIRIDINOILPIPERIDINA 5-HT1F | ⤷ Sign Up |
| Ukraine | 124433 | ПІРИДИНОЇЛПІПЕРИДИН, ЙОГО ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ МІГРЕНІ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ (COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS) | ⤷ Sign Up |
| China | 100352817 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
